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Multimodality Somatostatin Analog for Fluorescence-Guided Surgery in Cancer
Abstract
Servando Hernandez Vargas, B.S.

Advisory Professor: Ali Azhdarinia, Ph.D.

Cancer surgery remains the primary curative treatment for most solid cancers and has major
therapeutic implications for patients with neuroendocrine tumors (NETs). Anatomical and
functional imaging technologies are widely used during the pre- and postoperative stages, but
intraoperative disease recognition relies on direct visual inspection and the hands of surgeons.
The limited number of clinical tools for real-time intraoperative visual feedback restricts the ability
to remove the complete cancer source and is partially responsible for the high rate of disease
recurrence in patients. Intraoperative imaging with fluorescent contrast agents has the potential
to improve the ability of surgeons to detect tumors when compared to visual inspection and hands
alone. Growing clinical evidence highlights the utility of fluorescence-guided surgery (FGS) in
cancer. However, the translation of fluorescently labeled imaging agents has been limited by the
semi-quantitative nature of the optical signal. Strategies to combine radioactive and fluorescent
contrast have been developed to enable cross-validation of fluorescent agents with nuclear
imaging and quantitative analysis. While several methods for dual labeling have been proposed,
the selection of a clinical radiotracer as a model system provides a proven targeting approach.
Since adding a fluorophore to a radiotracer could adversely affect its imaging properties, we
developed a multimodality chelator (MMC) to synthesize a bioactive analog of the NET imaging
agent,

Ga-DOTA-TOC. The MMC serves as a “radioactive linker” to bridge the near-infrared

68

fluorescent (NIRF) dye IR800 and targeting moiety Tyr-3-octreotide (TOC), producing
MMC(IR800)-TOC. Here, we first examined the radiochemical and pharmacological properties
of the dual-labeled analog. Subsequently, we evaluated the ability of the fluorescent somatostatin
analog to selectively target tumors that overexpress the somatostatin receptor subtype-2
(SSTR2) and demonstrate utility for FGS. We used

v

67

Ga/68Ga for quantitative biodistribution

studies and cross-validated semi-quantitative findings from fluorescence-based detection
methods. The observed receptor-mediated uptake in mice was confirmed via ex vivo analysis at
the macro-, meso- and microscopic levels. These results showed the impact of dual labeling on
tracer validation and the effectiveness of the MMC technology for developing a novel FGS agent.
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CHAPTER 1: INTRODUCTION

1

The role of surgery in cancer
The significant role of cancer surgery in patient care continues to evolve alongside
breakthroughs in medical and molecular oncology (1). Beyond being an isolated and radical
specialty, surgical oncology also extends to cancer prevention, diagnosis, staging, risk-reduction
and multidisciplinary management. Historically, surgery has served as the first-line therapy for
risk- and symptom-reduction for most solid cancers, and can be curative if complete resection is
achieved (1–5). However, the presence of positive surgical margins (PSMs) occur when the
surgical procedure does not remove the entire tumor and cancerous cells are left behind (6–10).
As outlined by the International Union Against Cancer (UICC), the extent of residual cancerous
tissue serves as a prognostic factor and may determine patient outcomes (11, 12).
Several surgical procedures are routinely employed for debulking or relieving symptoms.
However, the ultimate goal of cancer surgery is to remove the complete source of the disease
while sparing healthy tissue. Anatomical and molecular imaging technologies are available during
pre- and postoperative stages for surgical planning and surveillance, respectively. Conversely,
intraoperative disease recognition relies on direct visual inspection by the surgeon along “handson” palpation and tactile-guidance (1). As a result, significant effort has been made to bridge
preoperative imaging with real-time intraoperative imaging to address a critical unmet need in
cancer surgery.

Challenges, unmet needs and new technologies in surgical oncology
The advent of minimally invasive and robotic-assisted surgeries have revolutionized the
surgical standard of care and improved patient outcomes (1, 4, 5). Despite the surge of
technological advances in the operating room (OR), surgeons continue to rely on palpation and
visual inspection for the discrimination between diseased and healthy tissue. Lesions that are
undetectable to the naked eye, i.e., occult or too small, further complicate the ability of surgeons
to differentiate cancerous from healthy tissue intraoperatively. In this context, the available gold
standard for the semi-real-time intraoperative evaluation of PSMs is based on histopathology
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(13, 14). However, frozen section analysis has inherent challenges that may require extensive
sampling of the wound bed and adjacent areas. This labor- and time-intensive method can also
lead to the unnecessary removal of physiological elements or the partial extraction of diseased
tissue (13–15). Patients with residual cancer clusters left behind due to incomplete resections or
inconspicuous micrometastases have been shown to have a high recurrence rate and worse
prognosis (6).
To improve upon existing methods for intraoperative tumor identification, live navigation
using light-emitting agents that color code the surgical field of view has emerged as a promising
alternative (16–18). Enhancing intraoperative disease mapping via optical imaging is projected
to cause a paradigm shift in surgical oncology. The benefits of using fluorescence-guided surgery
(FGS) would not only support current guidelines focused on preservation of anatomical structures
(7, 8), but would also complement rapidly expanding minimally-invasive and robotic technologies
where tactile-guidance is not possible (1, 7, 8).

The nature of biomedical optics and its role in clinical oncology
The foundation of in vivo optical imaging is based on the movement of photons through
tissues and their interaction with tissue elements. Living organisms have endogenous contrast
that originates from many biological substances, which dictate the extent of photon scattering
(attenuation), absorption and emission (autofluorescence) characteristics of the living system
(19, 20). These dynamic phenomena have been used to produce visual contrast, thus generating
an opportunity for the application of biomedical optics (21). Alternatively, fluorescent signal can
be produced through administration of exogenous contrast agents. These agents have clinical
utility and are generally categorized based on whether the photons emitted are in the visible
electromagnetic spectrum (400-600 nm) or in the near-infrared (NIR) region (700-900 nm) (22,
23).
The first clinical use of a fluorophore for enhancing the real-time localization of tumors
dates back to 1948 when surgeons used fluorescein (ex/em = 494/512 nm) to aid in the
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localization and identification of intracranial neoplasms (24). The authors concluded that
fluorescein proved useful in confirming the presence or absence of neoplastic tissue.
Additionally, the authors suggested the contrast-enhancing technique as a method for evaluating
the state of infiltrating gliomas during surgery. Since then, the clinical benefits of fluorophores
have supported the expansion of food and drug administration (FDA)-approved visible
fluorescent agents (Table 1) for tumor detection and sentinel lymph node (SLN) mapping, as well
as others (18). However, the wide-spread clinical translation of visible fluorophores has been
restricted by their relatively low maximum resolution and penetration depth. These limitations are
a result of the complex optical properties of the dyes, predominantly a combination of
autofluorescence and photon attenuation that are particularly amplified in the 400-600 nm range
(21) (Fig. 1).

Table 1. Currently used Food and Drug Administration-approved fluorescence probes. Table
as originally published with permission from Nagaya T, Nakamura YA, Choyke PL and Kobayashi
H (2017) Fluorescence-Guided Surgery. Front. Oncol. 7:314. doi: 10.3389/fonc.2017.00314.
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Figure 1. NIR fluorescence is more suitable for in vivo imaging applications than visible-light
fluorescence. Near-infrared (NIR) fluorophores (700–900 nm) have deeper tissue penetration
and lower background fluorescence than visible-light fluorescence, resulting in enhanced
signal-to-noise ratios. The detection depths achievable with the currently available
instrumentation ranges from millimeters with NIR fluorescence to micrometers with visiblerange fluorescence. Figure as originally published with permission from Ray R. Zhang, Alexandra
B. Schroeder, Joseph J. Grudzinski, Eben L. Rosenthal, Jason M. Warram et al. (2017). Nat Rev
Clin Oncol. doi: 10.1038/nrclinonc.2016.212.
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Fluorophores in the NIR spectrum provide several advantages that make long-wave
imaging specifically suitable for clinical use. This includes enhanced photon transport that leads
to higher penetration depths. It also results in lower background signal due to reduced
autofluorescence and photon scattering (Fig. 1) (25). The increasing demand for NIR dyes has
been accompanied by the commercialization of FDA-approved NIR imaging devices (Table 2),
which consist of an excitation light source, collection optics (filters), a NIR camera and a display
unit (Fig. 2) (26, 27). Customization of the acquisition features of the imaging device can result
in improved resolution and sensitivity with reduced amounts of dye (28). Thus, the concomitant
development of a drug intended for use with a specific device (drug-device combination) can
strongly support translational efforts.
Thus far, the clinical adoption of NIRF imaging has been restricted to the high-dose
administration (up to 25 mg) of the non-targeted dye, indocyanine green (ICG, ex/em = 785/830
nm). ICG has been widely used for the assessment of blood flow and tissue perfusion, SLN
mapping, and tumor margin delineation (29–31). Since ICG lacks functional groups for
bioconjugation, there has been an increasing demand for new NIR beacons that can build upon
its clinical success, while providing improved stability and optical properties (25, 32).

6

Figure 2. The mechanics of NIR fluorescence imaging. NIR fluorescent contrast agents are
administered intravenously, topically or intraparenchymally. During surgery, the agent is
visualized using an NIR fluorescence imaging system of the desired form factor (above the
surgical field for open surgery, or encased within a fiberscope for minimally-invasive and
robotic surgery). All systems must have adequate NIR excitation light, collection optics,
filtration and a camera sensitive to NIR fluorescence emission light. An optimal imaging system
includes simultaneous visible (white) light illumination of the surgical field, which can be
merged with the generated NIR fluorescence images. The surgeon’s display can be one of
several form factors, including a standard computer monitor, goggles or a wall projector.
Current imaging systems operate at a sufficient working distance that enables the surgeon to
operate and illuminates a sizable surgical field. Abbreviations: LED, light-emitting diode; NIR,
near-infrared. Figure as originally published with permission from Alexander L. Vahrmeijer,
Merlijn Hutteman, Joost R. van der Vorst, Cornelis J. H. van de Velde, John V. Frangioni. Nat.
Rev. Clin. Oncol. 10, 507–518 (2013). doi: 10.1038/nrclinonc.2013.123.
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Table 2. Comparison of the various commercial fluorescence imagers for open-surgical applications based
on the key operational factors. Table as originally published with permission from Alisha V. DSouza, Huiyun
Lin, Eric R. Henderson, Kimberley S. Samkoe, Brian W. Pogue (2016). J. Biomed. Opt. doi:
10.1117/1.JBO.21.8.080901.

Strategies for targeted FGS agent development
Conjugating a fluorophore to a ligand that binds to a target overexpressed in cancer would
generate a disease-specific probe. The targeted approach would, in turn, require reduced
amounts of contrast agent (μg range), and potentially lower risks of toxicity and non-specific
signal (33). In its simplest form, the anatomy of a receptor-specific agent is comprised of a dye
attached to a targeting moiety via a standard chemical linker. Depending on the receptor of
interest, the targeting ligand may be a small molecule, antibody, peptide or other type of
molecule. To facilitate the development of targeted probes, fluorophores have been synthesized
to contain reactive groups for facile bioconjugation, i.e., via amine-reactive (i.e., NHS-ester) or
sulfhydryl-reactive (i.e., maleimides) crosslinker chemistry, copper-free click chemistry (i.e.,
DBCO), etc. IR800 (ex/em = 774/789 nm) has emerged as a preferred bioconjugatable NIRF
dye that positions as an excellent candidate for FDA-approval based on desirable optical
properties, robust in vivo photostability and demonstrated safety both pre-clinically and clinically
(17, 25, 34, 35).
Seminal first-in-human studies have shown the feasibility of utilizing targeted agents for
FGS in several cancers. Notably, these targeted optical agents have proven to significantly
enhance the identification/delineation of tumor deposits and increase resection-rates of
malignant tissue when compared to palpation and visual inspection alone. Van Dam et al.
reported the first clinical study with a targeted fluorophore and showcased the potential for
improved cytoreductive surgery (36). This successful first-in-human application used a folate
analog conjugated to fluorescein isothiocyanate (folate-FITC, ex/em = 495/520 nm) for tumorspecific intraoperative imaging of folate receptor-α (FR-α) overexpression. The subsequent rapid
expansion of targeted imaging probes in the NIR region is exemplified by the development of
OTL38, a folate analog conjugated to a NIRF dye (796 nm). OTL38 has been reported to enable
higher detection rates of malignant tissue during surgery in FR-α positive malignancies including
ovarian cancer (37), renal cell carcinoma (38), lung/pleural nodules (39) and others. Recently,
IR800 has been conjugated to clinically used antibody therapeutics, such as bevacizumab (40)
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and cetuximab (34), for successful receptor-mediated surgical navigation and tumor margin
assessment in breast cancer and metastatic head and neck cancer patients, respectively.
While the utility of FGS in cancer continues to be supported by growing clinical evidence,
the pathway for the successful clinical translation of optical probes is vague (41–45). The
laboratory-to-human translation of targeted imaging probes continues to be largely restricted by
the complexity of biomedical optics, the lack of a clinical benchmark and validation difficulties
posed by the semi-quantitative nature of the optical signal (17, 21). Efforts to address FDA
requirements have more often than not been particularly hampered by the lack of robust and
standardized validation methods. The general consensus is that in order for image-guided
surgery with fluorescent contrast agents to go from bench-to-bedside, it is fundamental to set
standards with defined metrics for reporting and quantification in FGS (46–48). These realities
have spurred increased interaction between surgeons, scientists and regulatory agencies to
critically assess the value of implementing the optical technology in the OR and to identify optimal
routes for its safe and efficacious translation (41–45).

Dual labeling as a validation strategy
It has been estimated that ~10% of the successful dye excitation events typically emit
radiation (49). The intrinsic low energy radiated photons are then highly scattered in tissue,
leading to signal loss and restricted depth of penetration, which significantly limits the acquisition
efficiency by the optical imaging device. This scattering phenomenon largely contributes to the
ambiguity associated with precisely measuring the fluorescent signal being produced (46–48).
To overcome these quantitative limitations, efforts towards the combination of NIRF (>750 nm)
and nuclear contrast into single, molecularly targeted agents have emerged (50–55). The
synergistic potential of the optical and nuclear modalities has been recognized as a promising
platform that allows the quantitative assessment of fluorescence-based imaging. The
complementary nature arises from the shared and overlapping characteristics, namely the use
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of labeled probes, photon processing, comparable detection sensitivities (high picomolarfemtomolar range), and the need to extract quantitative data. (43).
Dual labeling provides a framework that leverages the key strengths of each technique
and overcomes the individual drawbacks from fluorescence-based and radionuclide-based
monolabeled probes. More precisely, the development of such dynamic platforms allows the
integration of signal reporters that synergistically provide higher spatiotemporal resolution and
higher penetration depth, by means of low energy (1-2 eV) and high-energy photons (~80-511
keV), respectively. Dual labeling also provides intrinsic validation through correlation of colocalized NIRF/radionuclide signals in tissues. Moreover, dual labeling serves as a method to
quantitatively assess pre-clinical NIRF imaging using standard nuclear imaging descriptors such
as % injected dose per gram of tissue (%ID/g) (50–55). Importantly, dual labeling has the
potential to extend preoperative surgical planning into the OR for real-time intraoperative cancer
detection.
Given the ambitious nature of the dual labeling strategy, several design challenges need
to be addressed. Depending on the structural scheme, the final multimodal reporter typically
consists of a ligand, a linker, a chelator and the fluorescent dye – components which taken all
together may be as large as the targeting moiety itself (50, 51, 55). In designing a NIRF/nuclear
probe, maximum retention of optical characteristics, radiochemical properties, receptor affinity
and biodistribution is desirable. Thus, careful consideration of the type/position of labels and the
size relation is critical. Indeed, the literature is replete with instances where the chelator-isotope
combination, radiochemical formulation or increase in molecular weight, significantly influenced
the dye stability (56), coordination chemistry (57)

or pharmacodynamic/pharmacokinetic

properties (58–60), respectively, via alterations in the charge distribution and hydrophobicity
characteristics.
Heptamethine cyanine dyes are the most commonly used fluorophores for dual labeling
based on their longer-wavelength fluorescence, high quantum yield, high photostability and a
range of bioconjugatable derivatives (61, 62). This class of NIR dyes consists of aromatic
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heterocycles bridged by polymethine chains, which may be functionalized with cyclohexenyl
substitutions to improve their photophysical properties. Additionally, sulfonic acid groups have
been added to certain dyes to increase hydrophilicity. Nonetheless, the inherent lipophilic nature
of fluorescent molecules, coupled with their generally uneven charge distribution, pose
challenges in maintaining the rapid clearance properties of peptides. Specifically, IR800 has a
hydrophobic core with a highly anionic surface charge and has been reported to primarily clear
through the liver (63, 64). Previously, it has been shown that upon IR800 conjugation, a cyclic
Arg-Gly-Asp (RGD) analog had a -4 net charge with an unbalanced charge-to-hydrophobicity
distribution. Although the tumor targeting capabilities were not affected by such physicochemical
properties, the IR800 conjugated RGD analog showed higher nonspecific accumulation in the
liver and abdominal/thoracic walls when compared to a fluorescent RGD analog with 0 net charge
and a well-balanced charge distribution (64).
Proof-of-concept studies have shown that dual labeling can be practical in the pre-clinical
setting for the characterization of promising candidates for targeted FGS. For instance, the RGD
peptide has been functionalized with the ICG analog, cypate, and
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In-DOTA for angiogenesis

evaluation via αvβ3 integrin overexpression (65). The multimodal RGD derivative was found to
retain in vitro receptor affinity and to target tumors in vivo as determined by consistent radioactive
and fluorescence intensity data, indicating labeling did not interfere with binding properties. In
another study, Zhang et al. developed the first bimodal positron emission tomography
(PET)/fluorescent probe for gastrin-releasing peptide receptor targeting and assessed receptorbinding affinity upon dye conjugation (66). Using PET/CT and fluorescence imaging along crossvalidation via biodistribution studies, the authors showed receptor-mediated uptake and high
multimodal image contrast with potential for clinical translation. Similarly, Baranski et al. reported
the synthesis and evaluation of a library of dual labeled agents derived from the radiotracer 68GaPSMA-11 for prostate-specific membrane antigen targeting (67). The authors found that the
development of fluorescent-PSMA-11 analogs is feasible and concluded that these multimodal
agents are promising candidates for pre-, intra- and postoperative imaging of prostate cancer.
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Selection of neuroendocrine tumors as a disease model for FGS
The selection of a clinically established ligand-receptor complex as a model system would
logically support the characterization of an FGS agent. This rationale is especially applicable to
the somatostatin ligand-receptor system, a hallmark in neuroendocrine tumors (NETs). NETs are
a heterogeneous family of slow-growing, poorly understood neoplasms with a mostly sporadic
etiology and small familial risk (68) that would greatly benefit from the advantages provided by
FGS given their propensity to form micrometastases (69–71). Although NETs are classified as
relatively uncommon tumors, the 20-year limited-duration prevalence rate for the US population
was estimated to have a 1.7-fold increase from 2004 (103,312) to 2014 (171,321) (72). They also
have an annual overall incidence rate (6.3%) rising more rapidly than other more widespread
cancers (i.e., lung and breast cancer) (73, 74). Because of the extended distribution of
neuroendocrine cells across the body, NETs have a large spatial incidence encompassing the
foregut, midgut and hindgut, with primary tumor sites occurring commonly in the lungs and
gastrointestinal tract (68, 75). NETs are generally categorized as well-differentiated (low to
intermediate grade) or poorly-differentiated (aggressive, high grade) based on factors such as
histopathology, proliferation rate and functional status. Functioning tumors lead to additional
debilitating symptoms due to excess peptide and hormone secretion and are routinely treated
with somatostatin analogs (SSAs), the only proven therapy for hormonal hypersecretion in NETs
(76).
The somatostatin receptor (SSTR) is a distinctive feature of NET biology and is
overexpressed in 75-95% of the cases. Although the SSTR family is composed of 5 types of Gprotein coupled transmembrane receptors, the SSTR type 2 (SSTR2) is the most abundant
subtype and has proven to be a fundamental target for diagnostic imaging and treatment with
SSAs (77). Two mechanisms of SSTR2 signaling and regulation are key for the clinical
effectiveness of SSAs. First, SSTR2 coupling to adenylyl cyclase (AC) via pertussis-toxin
sensitive Gi/o proteins inhibits AC, closes voltage-sensitive calcium channels and opens specific
potassium channels (78). This in turn causes a reduction in two critical second messengers,
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cyclic adenosine monophosphate (cAMP) and cytosolic calcium, which results in a synergistic
inhibitory effect on hormonal hypersecretion (77). Second, rapid receptor phosphorylation leads
to the desensitization and internalization of the ligand-receptor complex via clathrin-coated pits
(78) that allows the intracellular accumulation of SSAs. Given the current clinical use of SSAs
that have been iteratively optimized over the last 30 years, NETs are an ideal disease model for
the development of an SSA-based FGS agent.

Evolution of SSAs and therapeutic management of NETs
The bioengineering of the first generation FDA-approved, eight amino acid SSAs
octreotide (peptide sequence, -D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)) and lanreotide
(peptide sequence, --D-NaI-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2) has served as the basis for
the treatment of functioning NETs (77). The therapeutic benefits of these SSAs are a result of
their ability to inhibit the secretion by and growth of SSTR2-overexpressing tumors. Octreotide
was first synthesized in 1982 (79) and entered clinical trials in 1984 (80). The synthesis of
lanreotide was first reported in 1987 (81) with clinical studies beginning in 1989 (82). Both SSAs
are synthetic agonists that have high SSTR2 affinity, lower SSTR3/SSTR5 affinity and no
SSTR1/SSTR4 affinity (77). Importantly, these SSAs activate SSTR2 at similar nanomolar
concentrations compared to the native counterparts, somatostatin-14 and somatostatin-28 (83).
Because of their highly improved in vivo stability, octreotide and lanreotide have been further
functionalized with radioactive elements and structural complexes capable of trapping isotopes
for nuclear imaging. Octreotide was the first SSA to obtain clinical importance (84), which led to
the development of a radiolabeled analog, iodine-123 labeled Tyr-3-octreotide (TOC), in 1989
for localizing tumors with a gamma camera (85). This initial success was followed by FDAapproval of
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In-labeled DTPA-D-Phe1-octreotide (OctreoScan) in 1994 (86), the first

radiopharmaceutical that was routinely used in the clinic for planar/SPECT imaging and radioguided surgery. The subsequent introduction of the metal chelator, DOTA (1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid) (87, 88), remarkably improved the stability of
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radioconjugates and permitted the implementation of PET isotopes (i.e.,
imaging and theranostic isotopes (i.e.,

90

Y,

68

Ga,

64

Cu) for NET

177

Lu) for peptide receptor radionuclide therapy

(PRRT).
Advances in the management of NETs have translated into earlier, more precise
diagnoses with

68

Ga-DOTA-TOC and

68

Ga-DOTA-TATE (structural analog with acidic C-

terminus) as the PET imaging gold standards. Additionally, improved therapeutic options have
emerged, including PRRT (89) and the approval of new targeted drugs (90). Despite these
advances, surgery remains the only potential curative treatment for NETs. Importantly, surgery
for NETs is indicated not only in localized cases, but also in advanced stages of the disease for
debulking and palliating the abnormal tissue/hormonal burden. Given the relatively indolent and
slow-growing nature of NETs, diagnosis is often delayed for many years, and at the time of
presentation, 40-70% of patients have nodal or liver metastases (76). Although surgery extends
the overall survival even in cases presenting metastatic disease, patients with NETs have a 5year recurrence rate of more than 90%. This recurrence is primarily attributed to residual disease
and incomplete removal of the cancerous metastatic lesions (69–71, 76, 91). Gamma probeguided ultrasound (92) and radio-guided surgery (93) have been implemented in the OR to
improve the detection of deep-seated and visually-challenging NET deposits. The added
advantage of radio-guided surgical navigation via audible signal is that the SSTR2-targeting
radiopharmaceutical used intraoperatively can also be used pre- and postoperatively for surgical
planning and postoperative surveillance imaging. However, the inability to obtain visual
information on tumor location significantly limits this approach. Consequently, fluorescent SSAs
are candidates that can address the limitations of radio-guided surgery.

The multimodality chelator (MMC) as a novel strategy for validating an FGS agent
Numerous examples of targeted optical probes in pre-clinical stages for NET diagnosis
and image-guided surgery are found in the literature (94). For instance, octreotide, octreotate,
TOC and TATE (Tyr-3-octreotate) have been coupled to a range of visible and NIR dyes including
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fluorescein (95), rhodamine derivatives (96) and cyanine dye derivatives (97–99). However,
validated FGS agents for SSTR2 targeting are lacking.
To support the validation and translation of FGS agents, we propose the application of a
novel, radioactive linker known as a multimodality chelator (MMC) that maximizes the distance
between the pharmacophore and the fluorescent label (100). The implementation of the MMC
permits “true” quantification and cross-validation through NIRF/nuclear signal co-localization. We
apply a translational focus to our dual labeling strategy with the MMC by developing a fluorescent
analog of the PET imaging gold standard in NETs, 68Ga-DOTA-TOC. Thus, we hypothesize that
SSTR2 targeting with

68

Ga-DOTA-TOC would serve as a proven model for a dual-labeled

SSA for FGS. To test this hypothesis, DOTA was substituted with the MMC, which minimized
the steric effects of dye labeling, while allowing the retention of the chelator-peptide footprint of
DOTA-TOC. The role of the MMC was subsequently redefined to serve as a radioactive linker
that maximizes the distance between the pharmacophore (TOC) and the NIRF label (IR800). The
arrangement of MMC(IR800)-TOC (Fig. 3) is possible because of the versatility afforded by the
macrocyclic compound DO2A (1,4,7,10- tetraazacyclododecane-1,7-bis(t-butyl acetate)), which
structurally mimics DOTA, but permits selective functionalization of the chelator. Upon synthesis
of an MMC with acetate and azide-containing pendant arms, Tyr3-octreotide (TOC) conjugation
was first performed using solid-phase peptide synthesis, and the resulting intermediate was then
fluorescently labeled with IR800 via copper-free click chemistry in solution, respectively.
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Figure 3. Structure and components of the SSTR2-targeted intraoperative imaging agent.
MMC-mediated dual labeling enables quantitative characterization of the fluorescent
somatostatin analog, MMC(IR800)-TOC.
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Previous efforts to develop somatostatin analogs for nuclear/NIRF imaging have been
attempted and major limitations were identified. For instance, Santini et al. successfully
synthesized the fluorescent/radiolabeled hybrid Cy5-111In-DTPA-Tyr3-octreotate (101); however,
upon dye conjugation, loss of binding properties was observed. In vitro uptake studies showed a
27.6-fold decrease in receptor binding compared to the monolabeled tracer

111

In-DTPA-Tyr3-

octreotate (33.76%±1.22% applied dose vs. 1.32%±0.02%). In another study, Edwards et al.
developed the multimodal SSA, cypate-labeled

64

Cu/177Lu-DTPA-Y3-TATE (102). Results

showed that despite having high in vitro binding affinity, the multimodal agent failed to internalize.
This indicates that the addition of cypate altered the mechanism of action of the somatostatin
agonist Y3-TATE. It was also reported that the high in vitro affinity did not translate to in vivo
tumor binding (≤1% ID/g). Additionally, the probe had predominant hepatobiliary clearance
(>90% ID/g of liver) and low kidney clearance, which is the inverse of traditional peptide-based
radiotracers. The authors attributed the low in vivo accumulation to the loss of internalization
rate, a hallmark of successful SSTR2-agonist imaging agents.
Our approach to dual labeling yielded the first bioactive fluorescent analog of a clinical
PET radiotracer (100), a strategy that further supports validation and translational efforts by
integrating components that can address current scientific concerns and regulatory hurdles.
Using

68

Ga-DOTA-TOC provides a foundation that aligns with current clinical practices in NET

management and a benchmark to guide optimization strategies. The use of the MMC technology
potentially extends the pre- and postoperative PET utility of

68

Ga-DOTA-TOC into the surgical

suite, while generating a method to quantitatively validate the resulting intraoperative imaging
agent. Importantly, 68Ga-DOTA-TOC would serve as an accompanying diagnostic for identifying
candidates that would benefit from FGS with Ga-MMC(IR800)-TOC. In this project, we assess
the performance and potential clinical utility of Ga-MMC(IR800)-TOC with the following specific
aims:

Aim 1. To determine the optimal radiosynthesis for
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68

Ga-MMC(IR800)-TOC: using clinically

relevant radiochemistry formulations (NaCl/acetone/fractionation), conditions will be optimized
based on high labeling efficiency and maximum retention of fluorescence intensity after labeling.
a) To quantify the radiochemical yield: radio-HPLC will be used to determine crude

68

Ga

complexation.
b) To assess the optical integrity: a fluorescence reader will be used to assess dye intensity after
radiosynthesis and normalized to unprocessed controls.

Aim 2. To characterize the binding properties of 68Ga-MMC(IR800)-TOC in vitro: quantitation
of receptor binding properties with radioligand assays will allow observation of SSTR2-cellular
uptake and specificity.
a) To quantify SSTR2-binding: cellular uptake will be examined using HCT116 cells that stably
overexpress SSTR2 (HCT116-SSTR2) and compared to 68Ga-DOTA-TOC.
b) To determine the specificity for SSTR2-binding: blocking studies will be performed with
increasing amounts of the SSTR2-competitor, octreotide.

Aim 3. To assess the imaging properties of

68/nat

Ga-MMC(IR800)-TOC in xenografts: using

an animal model with subcutaneous HCT116-SSTR2 tumors, the ability of the agent to provide
tumor contrast will be assessed in vivo and validated ex vivo.
a) To identify differences in the pharmacokinetics of

68

Ga-MMC(IR800)-TOC and

68

Ga-DOTA-

TOC: effects of dye labeling on the radiotracer will be determined by tissue biodistribution studies.
b) To determine specificity for localizing SSTR2-overexpressing xenografts: using PET/CT and
NIRF imaging, in vivo specificity (competition, non-targeted, control cell line) for cancer tissue
will be assessed and validated.
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CHAPTER 2: MATERIALS AND METHODS
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General methods
All chemicals were purchased from Sigma-Aldrich unless otherwise noted. Reversedphase high-performance liquid chromatography (HPLC) was performed on an analytical Hitachi
LaChrom system using a Kinetex C18 column (2.6 μm) (Phenomenex) with a mobile phase of A
= 0.1% TFA in H2O, B = 0.1% TFA in CH3CN (gradient: 0 min, 10% B; 12 min, 90% B); flow rate,
1 mL/min. Radiochemical purities of ≥95% were assessed by radio-HPLC using an in-line
radioactive detector (Berthold Technologies). 1H NMR and

13

C NMR spectra were recorded at

ambient temperature using 600 MHz IBM-Bruker Avance NMR spectrometers. Chemical shifts
(δ) were reported (in ppm) downfield of tetramethylsilane.

Labeling of MMC(IR800)-TOC with 68Ga, 67Ga, and Ga
68

Ga radiolabeling was performed using the acetone, NaCl and fractionation methods.

For the acetone method, radiolabeling was performed as previously described (100). Briefly, 68Ga
was eluted from a

68

Ge/68Ga-generator with 5 mL of 0.1 M HCl and adsorbed onto a Strata-X

cation exchange cartridge (Phenomenex). After purging residual HCl from the cartridge,

68

Ga

was collected with 98% acetone/0.02 M HCl (v/v) and 1 mCi was added to 20 nmol of
MMC(IR800)-TOC (MW: 2835.1 g/mol) in 0.2 M sodium acetate (pH 4). Samples were heated at
95° C for 15 min. Following Sep-Pak Light C18 (Waters) purification, the product was diluted with
PBS and analyzed by radio-HPLC. For the NaCl method, the radioactive solution was processed
identically to the acetone method with the exception of using a Bond Elut cation exchange
cartridge (Agilent), a 5 M NaCl/5.5 M HCl solution as an eluent and 2 M sodium acetate (pH 4)
as the reaction buffer. For the fractionation method,

68

Ga was eluted from the generator with 5

mL of 0.1 M HCl and collected separately as five 1 mL fractions. Only the fraction with the highest
radioactivity was selected for radiolabeling. 100 μL of peak fraction containing 0.3-0.4 mCi of
68

Ga was then directly added to 20 nmol of MMC(IR800)-TOC in 2 M sodium acetate (pH 4).

Finally, incubation, purification and analysis were performed identically to the acetone/NaCl
methods.
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For

67

Ga radiolabeling,

67

Ga-citrate was purchased from a radiopharmacy (Cardinal

Health) and was added to an equal volume of 0.1 M HCl to produce

67

GaCl3. The radioactive

solution was then processed identically to 68Ga using the acetone method, with the exception of
using 0.5 M ammonium acetate (pH 4.5) as the reaction buffer. Cold Ga labeling was performed
with non-radioactive gallium according to methods established above for the radiolabeled
compounds. 60 nmol was mixed with a 4-fold molar excess of GaCl3 and heated at 95°C for 15
min. The crude mixture was purified by ultrafiltration and the final product was characterized by
HPLC. Ga-MMC(IR800)- TOC: MS, ESI+: m/z calculated for C135H170N22O34S2Ga, 2905.01;
found m/z, 969.1 (M+3H)

3+

.

Optical characterization upon radiolabeling
MMC(IR800)-TOC was radiolabeled with 68Ga using the fractionation, acetone and NaCl
methods as previously described with the exception of using 1 nmol for the reaction. Briefly,
incubation was performed for 15 min at 95ºC in eppendorf vials. Reaction mixtures were purified,
collected in 1:1 saline ethanol solution and allowed to cool down for 30 minutes at room
temperature. Samples were then transferred to black 96-well half-area plates with clear bottom
(Greiner Bio-One). Fluorescence intensity was measured using an Odyssey plate reader (LICOR) and normalized to unprocessed MMC(IR800)-TOC in 1:1 saline ethanol solution. For the
mock, nonradioactive solutions, MMC(IR800)-TOC was processed identically to the radioactive
solutions with the exception of not adding 68Ga. Each experiment was performed in triplicate.

Cell culture and animal models
Athymic female nu/nu mice (Charles River Laboratories) were housed under standards
of the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Health
Science Center at Houston and maintained on normal rodent chow. HCT116-SSTR2 cells were
kindly provided by Dr. Carolyn J. Anderson (University of Pittsburgh, Pittsburgh, PA, USA).
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HCT116 cells (CCL-247) were purchased from ATCC. HCT116-SSTR2 and HCT116-WT cell
lines were cultured in RPMI 1640 medium with 10% (v/v) fetal bovine serum (FBS) and
maintained at 37°C with 95% humidity and 5% CO2 atmosphere. HCT116-SSTR2 cells were
additionally supplemented with 100 µg/ml Zeocin (Gibco). For all procedures, mice were
anesthetized with 1-2% isoflurane. For xenografting, 6-8 weeks old mice were subcutaneously
injected with 1×106 HCT116-SSTR2 or HCT116-WT cells in matrigel (Corning):PBS (1:1) in the
shoulder. Studies were conducted 3-4 weeks post implantation when tumor size reached
approximately 5-10 mm maximum diameter.

Measurement of intracellular cAMP with the GloSensor assay
HEK293-HA3-rsstr2-Glo cells, expressing both the GloSensor 22F cAMP plasmid
(Promega) and HA-tagged SSTR2 (from Dr. A. Schonbrunn Lab, The University of Texas Health
Science Center at Houston), were seeded at 100,000 cells/well in 96 well plates. After 24 h, the
medium was aspirated and replaced with 90 μL of warm (28°C) equilibration medium (DMEM +
10% FBS + 10 mM HEPES + 2% D-Luciferin). Plates were pre-incubated in a dark humidified
chamber at 28°C for 2 h and then placed in a PolarStar Optima multiplate reader (BMG Labtech).
Basal bioluminescence was measured and then 10 μl of NKH477 (final concentration = 10 μM)
was added either with or without the appropriate SSA concentration. Readings were taken every
2.5 min for 1 h. Data shown were obtained 20 min after agonist addition and are expressed as a
percentage of the luminescence measured in the presence of NKH477 alone. Reprinted
(adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas, Melissa
Rodriguez, et al. Copyright (2017) American Chemical Society. doi: 10.1021/acsmedchemlett.7b00125. These experiments were performed by Dr. Melissa Rodriguez and Dr. Agnes
Schonbrunn in the Department of Integrative Biology and Pharmacology, McGovern Medical
School, The University of Texas Health Science Center at Houston (100).
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Measurement of receptor internalization
Changes in cell surface expression of SSTR2 were measured in HEK293-HA3-rsstr2
cells (from Dr. A. Schonbrunn Lab, The University of Texas Health Science Center at Houston)
using ELISA, as previously described (78). Briefly, HEK293-HA3-rsstr2 cells were incubated with
labeled peptides for 30 min at 37°C. After washing, cells were fixed, blocked with 1% BSA for 30
min, and incubated overnight at 4°C with mouse anti-HA antibody (1:10,000). Cells were then
washed with PBS and incubated at r.t. for 1 h with goat anti-mouse HRP-labeled secondary
antibody (1:10,000). Cell surface receptor level was determined by incubating for 45-60 min with
ABTS and then measuring optical density at 405 nm. Reprinted (adapted) with permission from
Sukhen C. Ghosh, Servando Hernandez Vargas, Melissa Rodriguez, et al. Copyright (2017)
American Chemical Society. doi: 10.1021/acsmedchem- lett.7b00125. These experiments were
performed by Dr. Melissa Rodriguez and Dr. Agnes Schonbrunn in the Department of Integrative
Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science
Center at Houston (100).
Radioactive uptake studies
HCT116-SSTR2 cells were seeded in 96-well plates (200,000 cells/well) and incubated
with a 10 nM solution of

68

Ga-MMC(IR800)-TOC or

68

Ga-DOTA-TOC at 37oC for 1 h. For

blocking, a 10 and 100-fold excess of octreotide was added prior to addition of the radiotracers
to determine receptor specificity. At the end of the incubation period, cells were pelleted, media
was removed, and cells were washed three times with PBS. The cells were then collected and
radioactivity was quantified in a Wizard2 automated γ counter (Perkin Elmer) to determine uptake
as percent of total radioactivity added. The procedure was repeated using non-SSTR2
expressing HCT116-WT cells. Non-targeted 68Ga-MMC(IR800) was also tested in both cell lines
to further demonstrate specificity. Each experiment was performed in triplicate. Reprinted
(adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas, Melissa
Rodriguez, et al. Copyright (2017) American Chemical Society. doi: 10.1021/acsmedchem-
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lett.7b00125.
Biodistribution in healthy mice
Normal 4-6 week old female, athymic, nude mice were injected intravenously with 740
kBq (20 μCi) of

68

Ga-MMC(IR800)-TOC or

68

Ga-DOTA-TOC. Under anesthesia, the mice were

euthanized by cervical dislocation at 15 min, 1, and 3 h post-injection. Selected tissues were
excised, weighed, and counted for radioactivity using the γ counter. The results were expressed
as percentage of the injected dose per gram of tissue (%ID/g) and represent the mean±SD of n
= 3 mice/time point. The total injected activity per mouse was determined from a known aliquot
of the injected solutions.

In vivo PET/CT imaging
Mice (n=3) were intravenously injected with 5.55 MBq (150 μCi, 4 nmol) of

68

Ga-

MMC(IR800)-TOC and non-invasive imaging was performed at 1 and 3 h after injection on a
Siemens Inveon small-animal PET/CT scanner as previously described (57). Region-of-interest
analysis was performed with the vendor software package (Inveon Research Workplace) to
obtain tumor-to-background (TBR) ratios.

In vivo NIRF imaging
Mice (n = 5) were intravenously injected with Ga-MMC(IR800)-TOC (2 nmol, 5.67 µg) and
imaging was performed at 3 and 24 h post-injection. In vivo NIRF images were acquired for 200
ms without background subtraction using a custom-built electron-multiplying charge-coupled
device (EMCCD) fluorescence imaging system at ex/em = 785/830 (103), and image analysis
was performed with the ImageJ software package (NIH). At the conclusion of the imaging studies,
the mice were euthanized and selected organs were excised and underwent ex vivo NIRF
imaging using an IVIS Lumina II (Perkin Elmer). For the selection of a radiolabeling method for
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in vivo applications, mice (n = 4 per group) were imaged at 24 h post-injection as previously
described with the exception of administering 68Ga-MMC(IR800)-TOC (0.5 nmol, 1.42 µg).

Biodistribution and ex vivo imaging
Mice with HCT116-SSTR2 tumors were intravenously injected with 370 kBq (10 µCi, 2
nmol) of

68

Ga-MMC(IR800)-TOC or

67

Ga-MMC(IR800)-TOC, and euthanized by cervical

dislocation under anesthesia at 3 h and 24 h post-injection, respectively. Selected tissues were
excised and underwent ex vivo optical imaging using an IVIS Lumina II with the following settings:
lamp level (high), excitation (745 nm), emission (ICG), epi-illumination; binning (S); FOV (C, 10);
f-stop (2); acquisition time (1 s). Region of interest analysis was performed with the vendor
software package (Living Image) to measure fluorescence signals and obtain tumor-to-tissue
ratios. Parameters were the same for all acquired images. At the completion of the optical
imaging studies, tissues were weighed and counted for radioactivity using a Wizard2 automated
γ counter. The total injected activity per mouse was determined from an aliquot of the injected
solutions. The results were expressed as %ID/g and represent the mean±SD of n = 5 mice/time
point. To examine specificity, uptake in SSTR2 negative HCT116-WT xenografts was examined
by in vivo and ex vivo optical imaging 24 h after injection of Ga-MMC(IR800)-TOC (2 nmol).
Tumors and key organs (muscle, pancreas, small intestine) underwent cryoconservation by
embedding in OCT and freezing on dry ice for subsequent mesoscopic and microscopic analysis.
The non-targeted Ga-MMC(IR800) analog was evaluated identically to the targeted agent.

Mesoscopic and subcellular localization of Ga-MMC(IR800)-TOC in tissue sections
Frozen sections (10 µm) of muscle, pancreas, small intestine and tumors (HCT116SSTR2 and HCT116-WT) from animals that were injected with Ga-MMC(IR800)-TOC (2 nmol)
24 h prior to necropsy were used to localize the IR800 signal within the tissue. Using an Odyssey
slide scanner (LI-COR), the sections were scanned and the fluorescence intensities in the 800
nm channel were quantified on 16-bit images using ImageJ. ROIs were drawn around the outline
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of each organ and means±SD were calculated using GraphPad Prism (n=3 mice/group).
Adjacent sections underwent hematoxylin and eosin (H&E) staining to permit morphological
analysis of the tissue.
To analyze Ga-MMC(IR800)-TOC distribution and receptor specificity at the cellular level,
frozen sections of HCT116-SSTR2 and HCT116-WT tumors (24 h post 2 nmol Ga-MMC(IR800)TOC injection) were fixed in 4% cold paraformaldehyde for 10 min and embedded in Mowiol
mounting medium. For counterstaining, we added NucSpot Live 488 nuclear stain (Biotium) to
the mounting medium (1:1000 dilution directly in Mowiol). Microscopic images were acquired on
a confocal microscope (SP8, Leica), equipped with a 730 nm laser for IR800 detection and a 488
nm laser for NucSpot Live detection, in combination with appropriate filters. These experiments
were performed by Dr. Susanne Kossatz and Dr. Thomas Reiner in the Department of Radiology,
Memorial Sloan Kettering Cancer Center, New York.

Immunohistochemical staining of SSTR2
To detect SSTR2 expression, immunohistochemistry (IHC) was carried out on frozen
sections of xenograft tumor tissue (HCT116-SSTR2, HCT116-WT) using the Discovery XT
processor (Ventana Medical Systems, Tucson, AZ) at the Molecular Cytology Core Facility of
Memorial Sloan Kettering Cancer Center. After thawing, sections were baked at 50ºC for 1 h,
followed by a 30 min incubation with Background Buster solution (Innovex, Richmond, CA).
Sections were then incubated with the anti-SSTR2 rabbit monoclonal antibody (Abcam) at 2.2
µg/ml for 5 h, followed by a 1 h incubation with biotinylated goat anti-rabbit IgG (Vector Labs).
For detection, a DAB detection kit (Ventana Medical Systems) was used according to the
manufacturer instructions. Sections were counterstained with H&E and cover-slipped with
Permount (Fisher Scientific). Slides were digitalized using a MIRAX Slide Scanner
(3DHISTECH). These experiments were performed by Dr. Susanne Kossatz and Dr. Thomas
Reiner in the Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, with
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the support of the Radiochemistry & Molecular Imaging Probes Core Facility and Molecular
Cytology Core Facility at Memorial Sloan Kettering Cancer Center.

Statistical analysis
Graphs and calculations were performed with GraphPad Prism (v 5.01). All data are
presented as mean±standard deviation (SD) as indicated. Group comparisons were performed
with one-way ANOVA (with Bonferroni’s post-tests) or two-tailed t-tests.
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MMC(IR800)-TOC efficiently chelates 68/67/natGa using clinically relevant formulations
DOTA provides high radiochemical yields alongside remarkable in vivo stability due to its
kinetic inertness. Thus, by developing MMC(IR800)-TOC to structurally mimic the chelatorpeptide footprint from DOTA-TOC, we hypothesized that our multifunctional chelator retains high
labeling efficiency using clinically applied formulations.
Ga is a positron emitter (β+ = 89%, Eavg = 740 keV, Emax = 1899 keV) with desirable

68

characteristics for peptide-based targeted imaging. With its 67.71 min half-life, 68Ga is compatible
with the rapid pharmacokinetic profile of radiopeptides (104). Commercial 68Ge/68Ga generators
68

are available for on-site production of

Ga. Thus,

68

Ga availability is not necessarily dependent

on a cyclotron schedule, but on the parent radionuclide in the generator (68Ge t1/2 = 270.95 days)
(105). By contrast, 67Ga is a gamma emitter (t1/2 = 3.26 days, Emax = 394 keV) that has been used
in its salt form (i.e.,

67

Ga-citrate) as a radiopharmaceutical for assessing tumors, inflammation,

infectious processes, etc., via scintigraphy and single-photon emission computed tomography
(SPECT) imaging (106). However,

67

Ga is produced by a cyclotron facility and distributed by

radiopharmacies.
Our results show that 68Ga-MMC(IR800)-TOC production using the fractionation, acetone
and NaCl formulations is achieved with high radiochemical yield (>80%) (Figs. 4a-c) and with
>99% radiochemical purity following purification with a C-18 cartridge (Fig. 5). Figure 5 also
shows the corresponding absorbance at 280 and 780 nm for purified
For

68

Ga-MMC(IR800)-TOC.

67

Ga-MMC(IR800)-TOC radiosynthesis, a modified version of the Zhernosekov et al.

formulation was developed in our laboratory as described in the methods section. The final 67Gaproduct was produced with high radiochemical yield (72.7±5.1%, uncorrected for decay) and
>99% radiochemical purity following purification (Figs. 6a and 6b). The stability was examined
by incubating

68

Ga-MMC(IR800)-TOC in mouse serum at 37oC for 3 h and analyzed by radio-

HPLC (Fig. 7). No significant breakdown products or demetalation occurred following incubation.
Finally, Ga-MMC(IR800)-TOC was produced using non-radioactive gallium and confirmed via
mass spectrometry. These results indicate minimal impact of dye conjugation on the chelation

30

properties of the macrocycle. Moreover, they show that the MMC is a suitable DOTA substitute
for Ga ions and can be used with multiple labeling methods.
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68

Figure 4. Radiolabeling MMC(IR800)-TOC with clinically relevant Ga formulations. (a)
Labeling conditions for each method. (b) HPLC chromatograms showing the radioactive trace
68

of crude, non-decay corrected Ga-MMC(IR800)-TOC. (c) Radiochemical yields using
fractionation, acetone and NaCl radiosynthetic methods. Data are presented as mean ±
standard deviation (n=3).
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Figure 5. Purified 68Ga-MMC(IR800)-TOC. HPLC chromatograms showing absorbance of
purified 68Ga-MMC(IR800)-TOC at 280 and 780 nm, and the radioactive trace.
Figure 5. Purified 68Ga-MMC(IR800)-TOC. HPLC chromatograms showing absorbance of purified 68GaMMC(IR800)-TOC
at 280 andwith
780 permission
nm, and the from
radioactive
trace.
Reprinted (adapted)
Sukhen
C. Ghosh, Servando Hernandez Vargas,
Melissa Rodriguez, et al. Copyright (2017) American Chemical Society. doi:
10.1021/acsmedchem- lett.7b00125.
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Figure 6.

67

Ga-MMC(IR800)-TOC. HPLC chromatograms showing the radioactive trace of (a)
67

crude and (b) purified Ga-MMC(IR800)-TOC.
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68

Figure 7. Stability of Ga-MMC(IR800)-TOC in mouse serum. HPLC chromatograms showing
68
the radioactive trace of Ga-MMC(IR800)-TOC in serum up to 3 h.
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Comparison of normalized fluorescence upon subjection to radiolabeling
Given the differences in buffer concentrations and eluting solutions when utilizing the
acetone, fractionation and NaCl methods for producing

68

Ga-MMC(IR800)-TOC, we evaluated

whether the selection of radiolabeling scheme resulted in differences in fluorescence intensity.
The normalized fluorescence intensity for each method is shown in Figure 8. For all 3
methods, the mock, nonradioactive solutions retained >94% of the initial fluorescence in NaOAc
buffers ranging from 0.2-2 M with eluting solutions specific for each scheme. Upon 68Ga addition,
the acetone and fractionation methods showed similar fluorescence retention of 95.7±2.5% and
94.6±2.1%, respectively. The NaCl scheme resulted in the normalized fluorescence decreasing
to a final value of 85.1±2.3%, which was significantly different to the acetone and fractionation
formulations (P < 0.05). This indicates that the addition of 68Ga to the NaCl reaction mixture is a
contributing factor leading to a reduction in NIRF signal. Although we cannot draw definitive
conclusions on the reasons leading to the significant decrease in fluorescence using the NaCl
formulation, these results suggest that the selection of radiolabeling method may alter the
spectral properties of 68Ga-MMC(IR800)-TOC.
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Figure 8. Normalized fluorescence intensity of MMC(IR800)-TOC. Radioactive and
nonradioactive (mock) solutions were prepared using three radiolabeling schemes
(fractionation, acetone and NaCl) and normalized with unprocessed MMC(IR800)-TOC. *P <
0.05. Data are presented as mean ± standard deviation (n=3).
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Ga-MMC(IR800)-TOC retains intact pharmacological properties
The selection of the well-characterized SSTR2 agonist 68Ga-DOTA-TOC as a system for
the development of a fluorescent counterpart provides an ideal benchmark to assess the
pharmacological impact of conjugating IR800 via the MMC linker.
Figures 9a and 9b show the potency of peptide conjugates for cAMP inhibition and
receptor internalization in HEK293-SSTR2 expressing cells. Using Ga-DOTA-TOC as a
reference standard, we found that Ga-MMC(IR800)-TOC is able to maximally inhibit NKH477stimulated cAMP formation with high efficacy in the sub-nanomolar range (0.066±0.012 nM).
NKH477 is a water-soluble forskolin derivative that directly activates AC and catalyzes cAMP
production (107). Also, Ga-MMC(IR800)-TOC effectively stimulates receptor internalization with
an EC50 of 48.7±9.9 nM, which was comparable to the EC50 for Ga-DOTA-TOC (16.6±3.7 nM).
These studies indicate that the MMC scaffold successfully minimizes the effects of dye
conjugation and allows the retention of agonist properties despite the addition of a bulky dye.
Thus, the MMC is an effective scaffold for production of a fluorescent DOTA-TOC analog with
intact pharmacological properties.

68

Ga-MMC(IR800)-TOC binds specifically to SSTR2 and comparably to 68Ga-DOTA-TOC
To further assess cellular binding, uptake and blocking of the radiolabeled hybrid SSA

was investigated according to published protocols (58). Results showed that 68Ga-MMC(IR800)TOC uptake was 25.0±1.7% (% of total radioactivity added) in HCT116-SSTR2 cells at 1 h (Fig.
9c). Uptake in parental, non-SSTR2 expressing, HCT116 cells was 1.9±0.9%. The findings were
in agreement with 68Ga-DOTA-TOC uptake (21.5 ±3.7%, Fig. 9c), further suggesting that IR800
conjugation did not impact SSTR2-mediated binding capabilities. To further evaluate whether the
MMC-dye complex was contributing to any non-specific binding, a non-targeted MMC analog,
68

Ga-MMC(IR800), was incubated with both SSTR2-expressing and non-expressing HCT116

cells. Figure 9c shows that at 1 h, there is negligible uptake of

68

Ga-MMC(IR800) by either cell

line. Blocking studies with increasing concentrations of octreotide yielded a dose-dependent
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reduction of

68

Ga-MMC(IR800)-TOC binding (Fig. 9d). The presence of a 10 and 100-fold

octreotide excess resulted in a 78.5±9.6% and 93.7±1.6% reduction in

68

Ga-MMC(IR800)-TOC

binding, respectively. Taken together, these results support the data from the in vitro
pharmacological assays and provide robust evidence that indicate receptor-mediated uptake of
the dual-labeled agent.
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Figure 9. In vitro characterization of
Ga-MMC(IR800)-TOC. Potency of peptide conjugates
for (a) cAMP inhibition and (b) receptor internalization in HEK293-SSTR2 expressing cells. (c)
Cellular uptake and (d) blocking of peptide conjugates in HCT116-SSTR2 and wild type HCT116
cells. *P < 0.0001. Experiments for (a) and (b) performed by Dr. Melissa Rodriguez and Dr. Agnes
Schonbrunn in the Department of Integrative Biology and Pharmacology, McGovern Medical
School, The University of Texas Health Science Center at Houston.
Reprinted (adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas,
Melissa Rodriguez, et al. Copyright (2017) American Chemical Society. doi:
10.1021/acsmedchem- lett.7b00125.
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68

Ga-MMC(IR800)-TOC undergoes time-dependent elimination in vivo
High biostability and hydrophilicity are desirable properties for a clinical imaging

radiopeptide since they favor the renal-urinary mode of excretion over hepatobiliary excretion,
thus enabling tumor visualization in the abdominal cavity (108, 109). 68Ga-DOTA-TOC has high
in vivo kinetic inertness and hydrophilicity (log P = -2.9) (110), allowing it to rapidly clear from
non-target tissues and provide a low noise floor to enhance tumor detection sensitivity.
To evaluate the impact of dye conjugation on the pharmacokinetics, we performed
radioactive biodistribution studies at 15 min, 1 h and 3 h post-injection and results are
summarized in Figure 10 and Table 3.

68

Ga-MMC(IR800)-TOC undergoes time-dependent

elimination from circulation and healthy tissues up to 3 h post-injection. Kidneys were identified
as the primary clearance route, which suggests that the fluorescent counterpart, despite the
addition of multiple aromatic groups, retains the hydrophilic character of the parent radiopeptide.
IR800 conjugation did increase clearance through the reticuloendothelial system (RES) (liver and
spleen) and resulted in longer circulation in blood, however, the radioactive fractions in these
tissues decreased progressively with time and may provide suitable tumor contrast in the
abdomen region at a delayed time point (i.e., > 3 h). At other sites of interest, such as the lungs,
high

68

Ga-MMC(IR800)-TOC signal was persistent up to 3 h, while the

68

Ga-DOTA-TOC signal

was significantly higher at the pancreas up to 1 h (P < 0.05). The radioactive signal decreased
over time for both agents in the remaining tissues.
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Figure 10. Radioactive biodistribution in healthy mice. Tissue uptake values for
68
MMC(IR800)-TOC and Ga-DOTA-TOC.
68

68

Ga-

68

Table 3. Biodistribution results (%ID/g) for Ga-MMC(IR800)-TOC and Ga-DOTA-TOC.

Reprinted (adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas,
Melissa Rodriguez, et al. Copyright (2017) American Chemical Society. doi:
10.1021/acsmedchem- lett.7b00125.
42

68

Ga-MMC(IR800)-TOC binds to SSTR2 xenografts in vivo and is visualized using PET/CT
68

Ga-DOTA-TOC combines rapid tumor accumulation (80% of the dose within 30

minutes), low non-specific binding and rapid renal clearance, with suitable contrast being
achieved 1 to 1.5 h after agent administration (86). To examine the tumor targeting properties of
the dual-labeled agent, MMC(IR800)-TOC was radiolabeled with 68Ga and administered to mice
bearing HCT116-SSTR2 xenografts for PET/CT imaging at 1 and 3 h post-injection.
Accumulation at the tumor site can be seen at 1 and 3 h (Fig. 11a), with tumor-to-background
ratios of 1.9±0.7 and 2.6±0.9 (Fig. 11b), respectively. PET/CT imaging was in agreement with
the pharmacokinetic data obtained in healthy mice. The highest signal was observed in the
kidneys, indicating renal clearance. Prominent lung and liver signal was also visualized at both
time points, indicating involvement of the RES organs during clearance. These results provide
evidence of in vivo SSTR2 targeting capabilities and suggest that delayed imaging (>> 3 h) may
provide increased contrast in the thoracic and gastrointestinal regions.
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Determination of optimal imaging time point
We previously observed that

68

Ga-MMC(IR800)-TOC undergoes time-dependent

clearance from circulation and tissues up to 3 h post-injection. Therefore, we selected the 3 h
time point for the initial in vivo NIRF imaging experiments. The in vivo kinetics of non-radioactive
Ga-MMC(IR800)-TOC were qualitatively and semi-qualitatively evaluated in mice bearing
subcutaneous HCT116-SSTR2 xenografts using a custom-built EMCCD fluorescence imaging
system.
Early optical imaging showed inconsistent tumor delineation, alongside prominent kidney
signal and background fluorescence in the thoracic and abdominal walls (Fig. 12a). We
hypothesized that this inconsistency was a result of low agent accumulation, slow elimination
from background tissues or a combination of the two. Thus, NIRF imaging was repeated 24 h
post-injection (Fig. 12a). Delayed imaging showed clear tumor delineation and contrast
enhancement. Semi-qualitative analysis of the normalized fluorescent signal indicates that the
contrast gain in the tumor is a combination of signal retention and a 2-fold signal reduction from
background regions (Fig. 12b).
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Figure 12. In vivo NIRF imaging of Ga-MMC(IR800)-TOC in mice. (a) Representative NIRF
images of Ga-MMC(IR800)-TOC were acquired in HCT116-SSTR2 xenografts at early and delayed
time points using a custom EMCCD fluorescence imaging system. Solid arrows indicate tumor,
dashed arrows indicate kidney. (b) Normalized fluorescence signal in tumor and background
tissue. * P< 0.005. Data are presented as mean ± standard deviation (n=5).
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Ex vivo quantitative analysis and nuclear/NIRF contrast determination
A major advantage for dual labeling an FGS agent is the inherent ability to quantify its
biodistribution for cross-validation of the optical data. Accordingly, the radioactive utility of the
MMC was used to produce dual labeled conjugates for early (3 h, 68Ga) and delayed (24 h, 67Ga)
biodistribution studies. Ex vivo evaluation by IVIS imaging of resected organs was in agreement
with in vivo results (Fig. 13a). Agent uptake in the tumor was similar at 3 and 24 h and clearance
was primarily through the kidneys. Moderate liver signal was observed at both time points, but
the early lung fluorescence was reduced to background levels at 24 h indicating washout from
non-target sites. Fluorescence was minimal at both time points in other healthy tissues and
importantly in sites that endogenously express low/intermediate SSTR2 levels (small intestine,
pancreas, and stomach) (111).
Analysis of fluorescence intensity is summarized in Figure 13b and Table 4, with
corresponding optical contrast ratios shown in Figure 13c. Accumulation of the fluorescent signal
in the tumor was rapid and sustained with no significant change up to 24 h, and was higher than
non-clearance organs. Clearance was primarily through the kidneys, which showed constant
signal over time. The NIRF signal decreased significantly at 24 h for most of the remaining tissues
and remarkably in the small intestine (22.8%, P < 0.01), muscle (29%, P < 0.05) and lung (51.3%,
P < 0.01). The reduction of the NIRF signal translated into 1.3 and 1.8-fold contrast
enhancements in tumor-to-muscle (P < 0.05) and tumor-to-lung (P < 0.05) ratios, respectively.
Importantly, the pancreas and small intestine had constant contrast ratios of >2.5, while for the
lungs, the ratio increased from 1.40±0.40 to 2.52±0.27, which is critical since a TBR of at least 2
is generally accepted as being suitable for tumor delineation in the operating room.
Radioactive biodistribution results are summarized in Figure 13d and Table 5, with
corresponding tumor-to-tissue ratios shown in Figure 13e.

At 3 h, administration of

68

Ga-

MMC(IR800)-TOC resulted in high renal clearance (45.6±3.8 %ID/g), along with prominent
accumulation in the lungs (6.7±0.9 %ID/g), liver (5.0±0.9 %ID/g), and stomach (4.5±0.8 %ID/g).
Tracer accumulation of 3.54±0.85 %ID/g was measured in the tumor and was higher than
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pancreas (1.7±0.2 %ID/g) and small intestine (1.3±0.1 %ID/g). Analysis of the 24 h biodistribution
data showed similar tumor uptake of

67

Ga-MMC(IR800)-TOC compared to the 3 h group

(4.26±1.08 %ID/g, P > 0.05). Importantly, reduction in signal was seen in most tissues that were
not involved in clearance. Most notably, tracer signal decreased by 64.6% in muscle (P < 0.01)
and 84.3% in blood (P < 0.001), yielding tumor-to-muscle and tumor-to-blood values of 18.9±3.7
and 11.5±3.4, respectively, and a 3.1-fold (muscle) and 7.1-fold (blood) increase from values
obtained at 3 h. In tissues relevant to NET surgeries, tumor-to-tissue ratios improved significantly
for the lung (P < 0.01) to a final value of 1.50±0.43 (2.8-fold increase).
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Figure 13. Quantitative biodistribution assessment by dual labeling. (a) Ex vivo optical images
(IVIS) of organs resected from HCT116-SSTR2 xenografts that were injected with
67

68

Ga-

MMC(IR800)-TOC or Ga-MMC(IR800)-TOC. Determination of (b) tissue fluorescence by
analysis of IVIS imaging and (c) corresponding contrast ratios at major sites of NET incidence
(pancreas, small intestine, lung) and selected non-target sites (muscle and blood).
Determination of (d) radioactive uptake by gamma counting and (e) corresponding gamma
counting ratios. * P< 0.05, ** P< 0.01, ***P< 0.001. Data are presented as mean ± standard
deviation (n=5). Average radiant efficiency displayed as ([p/s/cm²/sr]/[µW/cm²]). S.I., small
intestine.
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Table 4. Average radiant efficiency × 10

3

([p/s/cm²/sr]/[µW/cm²]) results for

67

MMC(IR800)-TOC and Ga-MMC(IR800)-TOC.
68

Ga-MMC(IR800)-TOC

67

Ga-MMC(IR800)-TOC

3h

24 h

Tumor

231,420 ± 60,115

205,075 ± 22,691

Muscle

50,478 ± 9,203

35,825 ± 1,259

Pancreas

90,390 ± 9,067

79,425 ± 13,594

S. Intestine

54,856 ± 4,742

42,345 ± 1,934

Lung

169,480 ± 38,156

82,583 ± 15,944

Liver

139,440 ± 17,199

162,650 ± 8,012

Spleen

58,998 ± 9,312

40,875 ± 1,963

Stomach

84,198 ± 11,288

60,978 ± 10,560

Kidney

1,152,800 ± 129,635

1,456,500 ± 302,673

Bone

87,696 ± 9,263

61,505 ± 7,635

Heart

60,228 ± 4,068

45,813 ± 12,630

Adrenal

93,834 ± 20,315

86,138 ± 42,056
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68

Ga-

68

67

Table 5. Biodistribution results (%ID/g) for Ga-MMC(IR800)-TOC and Ga-MMC(IR800)-TOC.
68

Ga-MMC(IR800)-TOC

67

Ga-MMC(IR800)-TOC

3h

24 h

Tumor

3.54 ± 0.85

4.26 ± 1.08

Muscle

0.64 ± 0.12

0.22 ± 0.05

Pancreas

1.67 ± 0.21

1.44 ± 0.13

S. Intestine

1.29 ± 0.13

1.05 ± 0.21

Lung

6.68 ± 0.89

2.90 ± 0.83

Liver

5.04 ± 0.88

5.03 ± 0.54

Spleen

3.16 ± 0.94

1.64 ± 0.46

Stomach

4.48 ± 0.77

2.85 ± 0.16

Brain

0.12 ± 0.06

0.03 ± 0.00

Blood

2.38 ± 0.23

0.37 ± 0.05

Kidney

45.58 ± 3.77

36.81 ± 2.64

Bone

1.80 ± 0.43

0.85 ± 0.04

Heart

2.12 ±0.82

0.55 ± 0.03

Adrenal

2.30 ± 2.85

1.11 ± 0.16

Urine

56.13 ± 18.23

5.14 ± 0.98
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Specificity for SSTR2 imaging in vivo
SSTR2-mediated-targeting of our optical probe was evaluated by using 1) mice with
HCT116-SSTR2 and HCT116-WT tumors, and 2) the non-targeted MMC analog, GaMMC(IR800), in HCT116-SSTR2 mice. In vivo imaging showed clear Ga-MMC(IR800)-TOC
signal in HCT116-SSTR2 tumors but not in WT tumors lacking SSTR2 expression (Fig. 14a). Ex
vivo IVIS imaging was in agreement with in vivo results (Fig. 14b) and subsequent image analysis
showed a higher (P < 0.01) average radiant efficiency emitted from the HCT116-SSTR2
xenograft compared to the WT tumors and non-targeted analog (Fig. 14c). This, in turn, resulted
in TBRs that were 1.8, 1,8, 2.3, and 2.4-fold higher than WT in the muscle, pancreas, small
intestine, and lung of HCT116-SSTR2 mice, respectively (Fig. 14d).
Mesoscopic analysis of frozen sections confirmed the in vivo and ex vivo imaging results
and showed specific, localized Ga-MMC(IR800)-TOC uptake only in HCT116-SSTR2 tumors
(Fig. 15a). H&E staining showed that agent uptake was confined to viable areas of the HCT116SSTR2 tumor, while no accumulation was observed in the WT counterpart (Fig. 15a). The signal
in HCT116-SSTR2 tumors was 8.6-fold higher than in SSTR2-deficient tumors, while the signal
in pancreas, muscle and small intestine are comparably low between the groups (Fig. 15b). On
the microscopic level, we observed an intracellular agent accumulation in HCT116-SSTR2
tumors, while we did not detect the NIRF signal in HCT116-WT tumors (Fig. 15c).
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Figure 14. In vivo and ex vivo specificity of Ga-MMC(IR800)-TOC. (a) In vivo NIRF imaging in
HCT116-SSTR2 and HCT116-WT subcutaneous xenografts acquired 24 h post-injection of GaMMC(IR800)-TOC with a custom-built EMCCD fluorescence imaging system. The non-targeted
Ga-MMC(IR800) in HCT116-SSTR2 mice was similarly evaluated. Arrows indicate tumor. (b) Ex
vivo NIRF imaging of selected organs using an IVIS Lumina II. (c) Tissue fluorescence determined
from analysis of IVIS imaging. (d) Optical contrast provided by the ratio of the average
fluorescent signal in the tumor to sites of NET formation. * P< 0.05, ** P< 0.01, ***P< 0.001.
Data are presented as mean ± standard deviation (n=5). Average radiant efficiency displayed as
([p/s/cm²/sr]/[µW/cm²]).
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Figure 15. Multiscale imaging of Ga-MMC(IR800)-TOC uptake. (a) Confirmation of in vivo
accumulation of Ga-MMC(IR800)-TOC in HCT116-SSTR2 and HCT116-WT xenografts and organs
via frozen section imaging using the Odyssey NIR scanner. H&E sections provide morphological
reference. (b) Quantification of the fluorescence signal of tumor and organ frozen section
Odyssey scans (Means and standard deviations of n=3 animals/group). (c) Microscopic
detection of in vivo injected Ga-MMC(IR800)-TOC. Frozen sections from resected HCT116SSTR2 and HCT116-WT tumors were counterstained with a nuclear stain (Nucspot488), fixed
and examined under a confocal microscope. An NIR signal was only detected in HCT116-SSTR2
tumor, corresponding to the SSTR2 expression in this model, while it was absent in SSTR2
negative HCT116-WT tumors. Experiments were performed by Dr. Susanne Kossatz and Dr.
Thomas Reiner in the Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York.
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Effect of injected dose on image contrast
The detection of small lesions while maintaining a high tumor-to-background ratio is a
major challenge for FGS. The answer to the question of “what is the smallest amount of cancer
that this technique can detect?” is a function of the sensitivity and specificity of both the optical
agent and the imaging device (41). Thus, we evaluated the interplay between injected amount
and contrast by comparing the effects of low (0.5 nmol) and high (2 nmol) dose administration of
Ga-MMC(IR800)-TOC in SSTR2-expressing tumors at 24 h. Ex vivo IVIS imaging showed higher
tumor fluorescence with the 2 nmol group. However, the higher dose also resulted in the amplified
non-specific accumulation of signal in non-target and healthy tissues (Fig. 16a). Image analysis
confirmed that although a larger dose yields a 3.8-fold increase (P < 0.001) in total fluorescent
output in the tumor, it also elevates fluorescence in non-tumor tissues and raises the background
signal by >6-fold in the pancreas, small intestine and lung (P < 0.001) (Fig. 16b). The increase
in NIRF signal at 2 nmol/mouse resulted in an approximately 40% reduction in tissue contrast
compared to 0.5 nmol/mouse (Fig. 16c). Since an elevated noise floor could offset the high signal
in the tumor and impair intraoperative visualization of NETs, we identified 0.5 nmol as the starting
point for future in vivo studies.
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Figure 16. Effect of injection mass on optical contrast. (a) Macroscopic NIRF imaging of
resected organs following administration of 0.5 nmol and 2 nmol. (b) Tissue fluorescence
measured by IVIS imaging following injection of Ga-MMC(IR800)-TOC at 0.5 nmol and 2 nmol
per mouse. (c) Optical contrast provided by the ratio of the average fluorescent signal in the
tumor to sites of tumor formation. * P< 0.05, ** P< 0.01, ***P< 0.001. Data are presented as
mean ± standard deviation (n=5). Average radiant efficiency displayed as
([p/s/cm²/sr]/[µW/cm²]).
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CHAPTER 4: DISCUSSION
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The gap between pre- and intraoperative imaging emphasizes the tremendous difficulties
of navigating the translational pathway and the need for new methods to validate FGS agents.
In an effort to overcome these difficulties, we hypothesize that the clinical radiotracer 68Ga-DOTATOC would serve as an ideal system for developing a fluorescent analog for the specific targeting
of SSTR2 for FGS in NETs. With the implementation of the innovative MMC linker, which
functions as a spacer and radioactive core to bridge TOC and IR800, we were able to generate
a fluorescent DOTA-TOC analog with minimal structural deviations. The application of the dual
labeling strategy permits cross-validation through “true” quantification and NIRF/nuclear signal
co-localization, while having

68

Ga-DOTA-TOC as a clinical benchmark facilitates pre-clinical

evaluation. Importantly, our approach complements SSTR2-targeted radiotracers (i.e.,

68

Ga-

DOTA-TOC and 68Ga-DOTA-TATE). The pre-operative PET with a gold standard will accurately
identify the number of lesions and will be combined with CT/MRI to establish a surgical plan. The
surgeon can then navigate per standard of care to the appropriate location and utilize the contrast
provided by Ga-MMC(IR800)-TOC to remove lesions.
Numerous methods are available for

68

Ga-DOTA-TOC radiosynthesis. For testing

68

Ga-

MMC(IR800)-TOC labeling, we selected the fractionation, acetone and NaCl methods as
formulations with translational relevance. Each one of these methods has advantages and
disadvantages that define their suitability for specific applications. Fractionation is a wellestablished radiochemical method where 68Ga is eluted from the 68Ge/68Ga-generator in fractions
and the portion with the highest activity (~80% of activity concentrated in 1 mL of eluate) is
selected for direct incubation with the tracer (112). Concerns with

68

Ge and metal (i.e., Zn(II))

breakthrough drove the development of alternate radiosynthetic procedures that include preconcentration and purification of the initial

68

Ga eluate using exchange chromatography.

Zhernosekov et al. reported the now widely adopted successful purification of the

68

Ga eluate

using a cation-exchanger with acetone recovery for high radiochemical yield (113). Recently,
Mueller et al. has substituted the use of the organic solvent acetone (desirable for medical
applications), with a NaCl-based solution for the production of radioconjugates with high specific
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activities (114). Here, using these clinical radiochemistry formulations, we found that the MMC
complex coordinates

68

Ga,

67

Ga and Ga with high radiochemical yield and stability in serum,

which suggests that the MMC is a suitable DOTA substitute for in vivo applications and a versatile
chelator for metals and radiometals. As we move forward with testing new dyes and targetingpeptides, this radiochemical flexibility would permit the customization and optimization of
radiolabeling conditions.
In a dual labeled format, the performance of the fluorescent dye critically depends on the
preservation of the stability and optical properties upon subjection to radiolabeling. Labeling
formulations require a wide range of buffers, eluting solutions, pH ranges, heating temperatures,
etc. These differing factors coupled to varying concentrations of radioactivity may impact the
spectral properties of the dye. In a previous study by our group (51), it was shown that the relative
brightness (RB) of IR800 remains relatively unchanged at room temperature in the presence of
Ga and in NaOAc solutions ranging from 0.1-1.25 M and pH 4-6. In a follow up experiment, IR800
was added to 1.25 M NaOAc (pH 4) and heated to 95° C for 10 min with varying levels of

68

Ga

activity to simulate in vitro (0.6 mCi, low), in vivo (1.6 mCi, medium) and human studies (4.1 mCi,
high). Results showed that while the RB remained >2 and similar to that of the non-radioactive
buffer system for the low and medium activity doses, the radioactive solution with the highest
dose caused the RB to drop below 2. Similarly, in the present study we evaluated whether the
selection of radiolabeling scheme resulted in differences in fluorescence intensity. The
fractionation and acetone formulations yielded the highest signal retention and results were in
agreement with previous work by our group. The acetone formulation was selected for
subsequent in vivo applications based on high fluorescence retention and the ability to purify/preconcentrate 68Ga for production of 68Ga-MMC(IR800)-TOC with high specific activity.
Retention of pharmacological properties is another crucial pre-clinical endpoint when
developing a targeted agent that combines NIRF and nuclear contrasts. Agonist-induced
mechanisms have been a paradigm used by radiolabeled SSAs for nuclear imaging and PRRT.
This paradigm is established on the putative ability of somatostatin agonists to inhibit cAMP
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production and to induce the internalization of the ligand-receptor complex (77, 78). Previously,
dual labeled SSAs have been reported to lose the ability to bind the receptor (101) and internalize
(102) upon dye attachment. Thus, we investigated the impact of fluorescent functionalization on
these

fundamental

radiotracer

characteristics.

We

examined

receptor

kinetics

with

pharmacological assays and radioactive uptake studies, which indicated that 68Ga-MMC(IR800)TOC maintains intact binding and molecular mechanisms of action at comparable

68

Ga-DOTA-

TOC potencies. These in vitro pharmacodynamic results have been confirmed by analysis of the
subcellular localization of the agent using confocal microscopy (100).
Image contrast is dependent on agent accumulation in tumors and clearance from
background tissues. In healthy mice, we found that

68

Ga-MMC(IR800)-TOC underwent time-

dependent elimination from circulation and background tissues up to 3 h post-injection. Since
similar findings were shown by PET/CT imaging in SSTR2-overexpressing xenografts, we
selected 3 h as the initial time point for in vivo NIRF imaging but found that tumors were not
clearly visualized. Given the continuous washout of agent from normal tissues, we extended the
imaging study to 24 h to enable further clearance and showed clear delineation of tumors in all
mice. Since optical imaging is not quantitative, we produced radioactive analogs for early (68Ga)
and delayed (67Ga) biodistribution studies to further evaluate tissue uptake. From those
experiments, we confirmed that clearance from background organs was the major factor
contributing to the improved focal signal being detected from the cancer lesion at 24 h.
Importantly, tissue uptake and contrast ratios obtained by gamma counting were essentially
identical to the ex vivo optical data and demonstrated the intrinsic utility of dual labeling as a tool
for validating an FGS agent.
The efficacy of an FGS agent has been defined by FDA guidance documents as the ability
to distinguish between normal and abnormal anatomy (42). Attempting to detect microscopic
disease in a macroscopic setting, namely the surgical field of view, further compounds the
difficulties of using an FGS agent effectively. Surgical resection of primary NETs is most
commonly performed in the pancreas, small intestine, or lungs. Therefore, low accumulation of
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Ga-MMC(IR800)-TOC in these tissues is necessary in order to generate suitable contrast for
determining surgical margins or lymph node metastases. Macroscopic ex vivo imaging showed
that our agent can provide contrasts of >2 in pancreas and lungs, and >4.5 in muscle and small
intestine. Importantly, these TBRs were acquired without dose optimization or an accompanying
imaging device. Suitable contrast ratios for FGS are difficult to define given the increasing
number of drug-device combinations in the OR. However, our results compare favorably to preclinical and clinical TBRs during fluorescence-guided resection of tumors (34, 39, 115) and
indicate potential for intraoperative visualization of NET deposits using Ga-MMC(IR800)-TOC.
Previous work by our group showed SSTR2-mediated uptake of a

64

Cu labeled

MMC(IR800)-TOC analog using in vitro and in vivo studies, where competition with octreotide
strongly reduced uptake in SSTR2 expressing tumors (57). In addition, a probe variant with a
scrambled peptide showed very low tumor uptake. The present study further confirms the intact
in vivo receptor specificity provided by TOC as shown by clear differences in tumor fluorescence
between HCT116-SSTR2 and HCT116-WT tumors macroscopically (in vivo, ex vivo) and
microscopically. Additionally, a non-targeted analog showed decreased tumor uptake.
Identifying the optimal injection dose can also attain improved image contrast. In the case
of radiotracers, both labeled (i.e.,

68

Ga-DOTA-TOC) and unlabeled (i.e., DOTA-TOC) species

are present upon administration and could result in competition for binding sites and reduce
radioactive signal in tumors. Fluorescent agents generally consist of a single chemical species
and do not experience such effects. Therefore, optical probes may not necessarily need to
adhere to microdoses and may benefit from increased agent dosage. Rosenthal et al. previously
showed that following the administration of 2.5, 25 and 62.5 mg cetuximab-IR800/m2, the TBRs
of resected human tumors using closed-field imaging were highest with the middle dose (34).
Since larger doses may also produce more non-targeted uptake that reduces contrast
and negatively affects specificity, we examined the correlation between injected dose and
absolute fluorescence by injecting xenografts with 0.5 or 2 nmol of Ga-MMC(IR800)-TOC.
Although the 2 nmol dose produced a nearly 4-fold increase in tumor fluorescence, TBRs were
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all higher with the low-dose cohort. This is likely attributable to non-specific binding of GaMMC(IR800)-TOC that is amplified at higher doses and suggests more effective tumor
visualization at lower injection amounts. Further dose optimization studies could identify maximal
TBRs that reduce the potential of false-positives and enhance predictive value and diagnostic
accuracy.
Recently, there has been a surge of interest in evaluating tumor margins with surgical
specimen mapping. This strategy consists in utilizing closed-field devices with a controlled
environment for back-table fluorescence imaging of surgical resections. This method has been
proposed as a complementary tool during in situ surgical navigation for screening intraoperative
margin samples and prioritizing the fluorescent ones for further examination. Clinical studies
have effectively integrated ex vivo macroscopic imaging as a validation method with implications
for fluorescence-guided pathology. In one study, the accumulation of panitumumab-IR800 in
surgical samples highly correlated with tumor location with sensitivities and specificities >89%,
while the NIRF signal predicted the distance of tumor tissue to the cut surface of the specimen
(115). In another study with bevacizumab-IR800, an analytical framework for correlating
intraoperative fluorescence signals with histopathology was applied and demonstrated an 88%
increase in detection rates of tumor-involved margins (116). In order to examine tissue mapping
with Ga-MMC(IR800)-TOC, we correlated SSTR2 expression via IHC with H&E staining and
NIRF signal accumulation in frozen sections prepared from mouse xenografts. While H&E
provides boundary demarcation of tumor from non-tumor tissue, IHC identifies and determines
the distribution of SSTR2 expression. Thus, this histopathological combination serves as a
method for assessing the binding and delineation specificity of Ga-MMC(IR800)-TOC. Frozen
section analysis of HCT116-SSTR2 xenografts treated with Ga-MMC(IR800)-TOC revealed
fluorescent delineation of tumor from non-tumor tissue in excellent agreement with tumor
morphology and expression status determined by H&E and IHC staining, respectively.
Conversely, negligible signal was produced from the SSTR2-defficient tumor and healthy tissues.
These results showed the potential clinical effectiveness of Ga-MMC(IR800)-TOC for specifically
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delineating tissues based on the presence of SSTR2 and indicate promising potential for imageguided NET pathology.
In summary, we demonstrated for the first time that an SSTR2-targeted FGS agent can
be used for highly specific tumor targeting. Importantly, we showed an excellent strategy for the
intact retention of agonist-induced mechanisms and in vitro/in vivo receptor-targeting capabilities
upon dye conjugation to the most commonly used SSA for PET imaging in NETs. Our results
also showed the effectiveness of the MMC technology for combining fluorescent and nuclear
contrast into a single targeted probe. We presented the advantages of applying the radioactive
utility of the MMC for cross-validating and quantifying the pharmacokinetics of the resulting FGS
agent. Finally, imaging at the macro, meso and microscopic scales provided comprehensive
validation of receptor-mediated uptake and strongly indicate translational utility for FGS in NETs.

Future Directions
There are two major areas that we are actively looking to investigate further. The first one
involves the determination of a strategy for significantly reducing the prominent liver signal that
we have observed up to 24 h. A decrease in liver signal could potentially allow the delineation of
SSTR2 overexpressing lesions in the hepatic system. This interest arises from the wellestablished role of neuroendocrine liver metastases that largely contribute to mortality rates in
NET patients. To put it into context, more than 40% of NET patients develop metastatic liver
burden over the course of the disease and have a 5-year survival rate ranging from 13 to 54%
(69). Our initial assessment will focus on further optimizing the injected dose and extending the
time for imaging relative to agent administration. The results of this study will provide insight to
the question “how low can we go and still acquire relevant TBRs?” at sites of NET formation.
Additionally, we will determine whether Ga-MMC(IR800)-TOC either requires more time for
clearance from the liver (i.e., signal at 24 h vs. 48 h) or whether dye conjugation causes
irreversible liver retention. Subsequently, we are interested in substituting the highly anionic
IR800 for a NIRF dye with comparable optical properties, but with reduced anionic burden and a
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well-balanced charge distribution over its surface (i.e., ZW800-1). We hypothesize that this
switch could improve the pharmacokinetic disposition of our FGS agent by means of faster
elimination from non-target tissues, while also reducing non-specific signal accumulation.
The second area that we are looking to further investigate is the sensitivity and specificity
of our FGS agent using a metastatic animal model. Clinically, SSTR2 overexpressing
malignancies will continue to be diagnosed using a gold standard. Importantly, patients that have
been identified as candidates for surgery using 68Ga-DOTA-TOC or -TATE, would be candidates
for FGS with Ga-MMC(IR800)-TOC. Thus, it is critical to evaluate the ability of our FGS agent to
target tumor deposits that have been previously identified using PET/CT with 68Ga-DOTA-TOC.
The results of this study will complement our strong in vivo specificity data and provide the
groundwork prior to transitioning to imaging larger animals (i.e., pigs) with 68Ga-DOTA-TOC and
Ga-MMC(IR800)-TOC.
Altogether, these findings will also serve as the basis and benchmark as we transition
towards the application of Ga-MMC(IR800)-TOC in other disease models with SSTR2
overexpression. Several tumors of the nervous system have been shown to express SSTR2 at
high density (77). Specifically, studies have shown that SSTRs are overexpressed in more than
90% of neuroblastoma (117) and medulloblastoma (118) tumors in children, while clinical studies
continue to investigate their implication for diagnosis and therapy (119). Recently, Dijkstra et al.
reported the establishment of SSTR2 as the “most promising receptor for meningioma targeting”
(120) with excellent potential for intraoperative imaging using targeted contrast agents. Thus,
candidates for surgery within this patient population could benefit from FGS with GaMMC(IR800)-TOC.
Finally, given versatility of the MMC technology, we are interested in expanding the role
of our radioactive linker for the assessment of not only targeting approaches beyond TOC (i.e.,
other peptides, small molecules), but for also evaluating other therapeutic strategies. The
conjugation of a reporter or payload to the MMC occurs through copper-free click chemistry – an
ever-growing field that facilitates the development of targeted probes through incorporation of
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reactive groups for facile bioconjugation. Therefore, the practicality of a “plug-and-play” platform
via the MMC provides an efficient method for the rapid synthesis and investigation of systemic
therapies including peptide-drug conjugates (i.e., with MMAE) and photodynamic therapy (i.e.,
with IR700DX). These theranostic agents could be a valuable alternative for patients with
advanced stages of SSTR2-positive metastases, where surgery may not be an option.
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